Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
rlcv-miR-rL1-28-3p
nsp13
Potential treatment - pre-clinical evidence Natural product Antiviral May/10/2021
aly-miR396a-5p
nsp13
Potential treatment - pre-clinical evidence Natural product Antiviral May/10/2021
Clofazimine
nsp13
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Apr/07/2021
Grazoprevir
nsp13
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/31/2021
Fludarabine
nsp13
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/23/2021
Paritaprevir
nsp13
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jan/20/2021
Simeprevir
nsp13
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Dec/02/2020
Polydatin
nsp13
Potential treatment - theoretical effect Natural product Antiviral Oct/22/2020
Tomentodiplacone B
nsp13
Potential treatment - theoretical effect Natural product Antiviral Oct/13/2020
Silydianin
nsp13
Potential treatment - theoretical effect Natural product Antiviral Oct/13/2020
Eryvarin M
nsp13
Potential treatment - theoretical effect Natural product Antiviral Oct/13/2020
Rhamnetin
nsp13
Potential treatment - theoretical effect Natural product Antiviral Oct/13/2020
Osajin
nsp13
Potential treatment - theoretical effect Natural product Antiviral Oct/13/2020
Raddeanine
nsp13
Potential treatment - theoretical effect Natural product Antiviral Oct/13/2020
Cangrelor
nsp13
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Sep/24/2020
Folic acid
nsp13
Potential treatment - theoretical effect Natural product Antiviral Sep/24/2020